1. Introduction
Hepatitis is an inflammation of the liver. There are at least five different viruses causing hepatitis. Each of the five major hepatitis viruses, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), delta hepatitis virus (HDV) and hepatitis E virus (HEV) belong to a separate family. Currently, all these viral hepatitis (A-E) have been classified into different genotypes and subgenotypes. Several factors, including viral genotypes have been reported to be associated with disease progression and treatment response. Consequently, documentation of genotype recently have been proved to be a valuable tool not only for epidemiological reasons but also for clinical implications and treatment.
2. Hepatitis A virus
HAV is a member of the
2.1. Disease severity
HAV causes an acute self-limited illness. The vast majority of hepatitis A patients make a full recovery and fatality rate is low. The estimated mortality rate is 0.1% for children less than 15 years old, 0.3% for adults ages 15 to 39, and 2.1% for adults ages 40 and old [10,11]. HAV does not lead to chronic hepatitis or a carrier state and only rarely leads to fulminant hepatic failure (FHF) [12]. FHF occurs during the first 4-6 weeks of illness which is characterized by sudden onset of high fever, marked abdominal pain, vomiting and jaundice followed by development of hepatic encephalopathy associated with deep coma and seizures [13,14]. Mortality is highly correlated with increasing age, survival being rare over the age 45 years [15]. The acute HAV super infection with chronic liver disease is also associated with severity and high mortality [16,17].
2.2. Genomic organization
Like all picornaviral genomes, HAV is divided into three parts: (i) 5’ non-coding region (NCR) that comprises approximately 10% of the genome (ii) single open reading frame (ORF) of 2227 amino acids, that encode all the viral proteins, with regions designated as P1 for capsid proteins, P2 and P3 for non-structural proteins and (iii) short 3’ non-coding region (Fig. 1).
HAV RNA genomes lack the cap assembly found at the 5’ end of mRNA species that normally guides the ribosomal complex to the translation start site [18]. Instead, an internal ribosome entry site (IRES) formed by the 5’NCR functions to initiate translations in HAV including other picornaviruses [19, 20]. However, unlike other picornavirus IRESes, the HAV IRES requires an intact eukaryotic initiation factor 4G for its optimal activity [20]. Several other host proteins are found to be associated with synthetic RNAs representing segments of the 5’ NCR [21]. The viral capsid protein (P1) is further divided into VP4, VP2, VP3 and VP1 regions. The non-structural P2 and P3 polyproteins are divided into 2A, 2B, 2C and 3A, 3B, 3C, 3D respectively (Fig. 1). HAV polyprotein is processed into precursor intermediates and mature proteins by the proteolytic activities of encoded viral proteins. HAV 2A, 2B, 2C protein encodes 45, 251 and 335 amino acids respectively. The 2A and 3C are identified as processing enzyme in hepatitis A virus. The translated 2A regions function as intermediary, partially located on the surface (VP1) and some are assembled inside the virion [20]. Both 2B and 2C proteins play an important role in the replication of the viral RNA. P3 polyproteins encodes 3A, 3B, 3C and 3D proteins with 74, 23, 219 and 489 amino acids respectively. 3C protein acts as sole protease for HAV protein processing, while 3D is the RNA dependent RNA polymerase [22].
2.3. HAV genotypes and geographic distribution
Genetic heterogeneity of hepatitis A has been revealed by sequencing different genome regions, including VP3 carboxyl terminus, the VP1 amino terminus and the VP1/2A junction [23-25] (Fig. 2). The VP3 C-terminal region is relatively conserved, the VP1 amino acid terminus presents an intermediate variability, while VP1/2A junction is more variable and is used to distinguish one strain from another [25]. The genetic variability observed within the putative VP1/2A junction (168 nucleotides) initially defined seven (I-VII) genotypes [26-29]. However, recently new classification of HAV has been done based on the complete sequences of the 900 nucleotides of VP1 region [30] (Fig. 2).
The phylogenetic analyses of VP1 sequences identified six genotypes (I-VI) that differ among themselves 15-25%. Three isolated from humans (I-III) and three from a simian origin (IV-VI). The genotypes I, II and III were further subdivided into sub-genotypes A and B, which differ in approximately 7.5% of base positions. The worldwide genotype distribution showed genotype I and III comprise the vast majority of human strains within the studied population (Fig. 3). Sub-genotype IA comprises the majority of the human strains studied and constitutes major virus population in North and South America, China, Japan, Russia and Thailand. The sub-genotype IB contains strains from Jordan, North Africa, Australia, Europe, Japan and South America. Most of the remaining human HAV strains segregate into genotype III that is further divided into two sub-genotypes, IIIA, and IIIB [23,27,29]. The sub-genotype IIIA have been subsequently identified in specimens collected from humans with hepatitis A in India, Sri Lanka, Nepal, Malaysia, Sweden and the U.S.A [26,31].The IIIB sub-genotype is responsible for cases of HAV infection in Japan and Denmark.
2.4. Effect of HAV genotype on disease severity
Although, HAV causes an acute self-limited illness but rarely, it also involved in severe course such as fulminant hepatitis, relapsing hepatitis, prolonged and cholestatic hepatitis. The question arises, if genetic heterogeneity/ genotypes play any role in self-limiting or severe course of the disease. There are contradictory reports regarding the role of HAV genotype in disease severity. Fujiwara
2.5. HAV genotype and antiviral treatment response
Since most of the cases are self-limiting, acute HAV does not require antiviral therapy in immunocompetent patients related to any genotype. The immunosuppressed patients should be recommended ribavirin, so that these patients should not progressed to cirrhosis. Liver transplantation is the only treatment option for patients with fulminant hepatic failure due to HAV. Since hepatitis A exists as a single serotype and human is the only host, it is possible to eradicate by selective vaccination against individuals who are susceptible and sero-negative for HAV-IgM.
3. Hepatitis B virus
HBV is a member of the
3.1. Disease severity
Chronic hepatitis B (CHB) is responsible for 1 million deaths per year globally [49]. It is a major cause of cirrhosis of the liver and hepatocellular carcinoma (HCC) worldwide [50,51].The integrity of the host immunological system, viral replication and probably the genetic heterogeneity (genotypes and mutations) of the (HBV) play an important role in the determination of the natural history [52,53]. However, the high morbidity and mortality associated with chronic HBV results in a substantial medical and economic burden on healthcare systems, marking HBV as an international health problem [52,53].
3.2. Genomic organization
HBV is an enveloped virus (42-47 nm in diameter) with an inner icosahedral nucleocapsid containing DNA genome [54]. The viral genome is approximately about 3.2 kb long, partially double-stranded relaxed circular (rc-dsDNA) structure and covalently bond to the viral encoded DNA polymerase [50,55-57]. The HBV genome has a highly compact coding structure consisting of four overlapping reading frames (ORF) designated as P (polymerase), S (surface/envelope), Pre-C/C (core) and X (HBx protein) (Fig. 4) [55,56,58].The polymerase ORF is the largest and it overlaps the X, the core and the pre-S/S. The pre-S/S ORF has 3 initiation codons encoding the small hepatitis B surface protein (SHBs), middle hepatitis B surface protein (preS2 + S) and large hepatitis B surface protein(pre-S1 + pre-S2 + S) proteins. C ORF encodes the core protein (HBcAg) and pre-core or e’ antigen (HBeAg) and it contains an N-terminal extension of 29 amino acids [55,56,58,59].
3.3. HBV genotypes and geographic distribution
HBV can be classified into 10 genotypes A to J, based on the comparison of complete HBV genomes [60-64]. These genotypes are based on a divergence of 8% or more in the complete nucleotide sequence of the entire viral genome [61-64]. There are numerous subgenotypes (currently approximately 24) has been identified based on genetic diversity of HBV [65,66]. These subgenotypes were differentiated by a sequence divergence by at least 4% [65,66]. Since genotypic variation of HBV is reflected in a partial sequence of HBV, therefore genotyping of HBV is possible without determining the entire genomic sequence [60,67,68]. As shown in Fig. 5, the S gene is more conserved than the pre-S region, therefore the analysis of the S gene is much more suitable for genotyping. Recently, a fragment of 1306 bp partially comprising HBsAg and polymerase coding regions(S/POL) has also been used for genotyping (Fig. 5) [69]. Several methods have been employed to genotype hepatitis B virus; (a) Direct sequencing [70] (b) Restriction fragment length polymorphism (RFLP) [71] (c) Line Probe Assay (LiPA) [72] (d) Genotype specific PCR [73].
The distribution of HBV genotypes varies across different geographical regions (Fig. 6). HBV Genotype A is most commonly found in the Americas, Africa, India and Western Europe [74,75]. Genotype B is most common in Asia including Japan, Taiwan, Indonesia, China and Vietnam [76-79]. Genotype C is predominant in East Asia and countries of the Pacific Rim [68], while genotype D most commonly found in the Mediterranean, India, Middle East [75,80-82]. HBV genotype E is mainly identified in sub-Saharan Africa, genotype F in South and Central America as well as Alaska, and genotype G in Central and North America as well as Europe [83-85]. The most recent HBV genotype identified, genotype H, has been found in the United States, Mexico and Central America [86,87]. The genotype F is the most distantly related genetically of the other HBV genotypes (12.8-15.5%) [88]. Recently, genotype I, a novel inter-genotypic recombination among genotypes A, C and G was isolated in Vietnam and Laos [89]. The newest HBV genotype J, was identified in the Ryukyu island in Japan, and this genotype has a close relationship with gibbon, orangutan and human genotype C [90]. The epidemiology of HBV infection is still shifting and the apparent variations in geographical distribution of genotypes is effect of migration from countries with a high prevalence of HBV infection to countries with a lower prevalence.
3.4. Effect of HBV genotypes on disease severity
There are conflicting report about the role of HBV genotypes and severity of the disease. Recent study from Japan demonstrated that genotype B is associated with slower progression to cirrhosis of the liver compared to genotype C [91]. Another study suggested that acute infection with HBV genotype A increases the risk of progression to chronic infection [79,92]. In China, the patients contracted with HBV subtype C2 develops chronic infection more often than those infected with subtype B2 [78,93]. There are conflicting reports from India; one study found that patients infected with genotype D strains had severe chronic liver disease, while another study could not find genotype D strains to be involved in severity [75,94]. Study from East Asia indicated, genotype C as a predominant genotype in subjects with advanced chronic hepatitis (CH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) [95]. Taiwanese study demonstrated association of genotype C as a risk factor for HCC than genotype B [93,96]. A study from Hong-Kong found that patients infected with genotype B had a higher rate of hepatic decompensation compared to genotype C patients [97]. The HBV patients contracted fulminant hepatitis are more often associated with genotype B [98]. The characteristics of other genotypes (E-J) with disease severity has not been well documented.
3.4.1. Do genotypes influence seroconversion and seroclearance?
The seroconversion of e’ antigen (HBeAg) and seroclearance of surface antigen (HBsAg) are important steps in the natural history of chronic HBV infection [99-102]. Early HBeAg seroconversion typically confers a favorable outcome, while late or absent HBeAg seroconversion after multiple hepatitis flares may accelerate the progression of chronic hepatitis to cirrhosis and hence a poor clinical outcome [99-102]. How these events are influenced by HBV genotypes are subject to a proper understanding and research? Taiwanese study demonstrated that genotype C infection was associated with lower rates of spontaneous HBeAg seroconversion than genotype B [101]. In case of HBsAg seroclearance, the HBV genotypes A and B patients had high frequency compared to genotypes C and D patients [83, 103].
3.4.2. Do genotypes influence frequency of viral mutations?
Several studies revealed that genotypes do influence the frequency of mutations in HBV genetic make-up. The HBV genotype C infections conferred a higher frequency of basal core promoter (BCP) A1762T/G1764A mutation than genotype B [104,105]. Similarly, patients with genotype D infection had a higher prevalence of BCP A1762T/G1764A mutation than those with genotype A infection [106]. The nucleotide(s) deletion within pre-S region is reported to be associated with genotypic variations. The pre-S deletion was higher in genotype C than genotype B patients [107]. In addition, the presence of pre-S deletion was an independent risk factor associated with disease progression as well as HCC development [108-110].
3.5. HBV Genotype and antiviral treatment response
According to different investigators, the nucleotide sequence diversity among different isolates of the virus may play a significant role in response to therapy. The impact of HBV genotype on therapeutic response has been reported in several studies [111,112]. HBV genotype plays a vital role in sustained response (i.e. normalization of serum ALT level and HBeAg seroconversion post treatment) rate. The HBeAg positive patients treated with standard IFN-a, the sustained response rate is significantly better in genotype A and B patients than for genotype C and D [113-116]. Contrary to genotype A-D, patients infected with genotype E–J are rarer and their responses to IFN-based therapy remain largely unknown. In patients treated with nucleos (t) ide analogues, sustained response rate was contradictory in relation to genotype [117,118].
4. Hepatitis C virus
HCV is a small size (55-65 nm), enveloped virus, belong to a member of the family
4.1. Disease severity
HCV is a major cause of liver associated disease all over the world with an estimated 3% of the world’s populations are chronically infected [129,130]. In some endemic areas, such as the Middle East, North-East Asia and South Africa, the prevalence of HCV infection is as high as 20-30% [122]. Chronic infection often progresses to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC) in a substantial number of patients [126-128]. The rate of disease progression is variable and several factors have been identified as important in predicting the outcome of progression such as age at infection, gender, genotype/subtype, viral load, and mode of infection.
4.2. Genome organization
HCV viral genome is positive sense RNA with approximately 9.4 kb in length containing a poly (A) tail at the 3’end (Fig. 7). The sequence contained a 5’untranslated region (5’ÚTR) of 341 bases and 3’UTR of about 27 bases [120,131, 132]. The HCV genome has a single open reading frame coding for a polyprotein of 3010 amino acids. The poly-protein is cleaved after translation into structural and non-structural proteins necessary for viral replication and virion formation. The structural proteins situated towards the N-terminus of the genome and non-structural genes located near C-terminal. The 5’UTR is most conserved region of HCV and is pivotal for the initiation of translation and ribosomal binding [133-135]. The structural genes code for the capsid (core) protein (C) and envelope glycoproteins (E1, E2) [133,134]. The first 27 amino acids of the E2 gene constitute the hyper-variable region 1 (HVR1) of the genome and seems to be involved in virus evasion of the immune system and disease progression [136]. The non-structural genes code for a protease (xlink, NS3) and its cofactor (NS4A), a helicase (NS3), a protein of unknown function (NS4B), a phosphoprotein (NS5A), and an RNA-dependent RNA polymerase (NS5B) [137].
The virus replicates in the cytoplasm using an RNA-dependent RNA polymerase that lacks general proofreading ability [138]. This error-prone RNA polymerase is responsible for the genetic variability exhibited by HCV isolates and high spontaneous nucleotide substitution rate with a frequency of 10–2 to 10–3 substitutions per nucleotide site per year [139]. HCV circulates as a heterogeneous population or quasispecies which differ by 1-5%in nucleotide sequence diversity [140]. Quasispecies permits rapid adaptability of the virus in the event of environmental changes and a clever strategy utilized by the virus to escape selective forces such as nucleotide antiviral agents or the immune system [139,140].
4.3. HCV genotypes and geographic distribution
The HCV genotype has been determined primarily based on analysis of partial genome sequences. Investigators have typically used sequence analysis of NS5B, core, E1, and 5'UTRs for HCV genotyping (Fig. 8). The most widely accepted classification system of HCV genotyping is that of Simmonds
At least 6 major genotypes of HCV, each comprising multiple subtypes have been identified worldwide [138,145-147]. Each genotype is separated by sequence divergence in the entire genome exceeding 30%. Substantial regional differences appear to exist in the distribution of HCV genotypes (Fig. 9). Although HCV genotypes 1, 2, and 3 appear to have a worldwide distribution, their relative prevalence varies from one geographic area to another [145]. HCV subtypes 1a and 1b are the most common genotypes in the United States [145]. These subtypes also are predominant in Europe [148]. In Japan, subtype 1b is responsible for up to 73% of cases of HCV infection [149]. Although HCV subtypes 2a and 2b are relatively common in North America, Europe, and Japan, subtype 2c commonly found in northern Italy [146]. HCV genotype 3a is particularly prevalent in intravenous drug abusers in Europe and the United States [150]. HCV genotype 4 appears to be prevalent in North Africa and the Middle East [151, 152], type 5 mainly in South Africa and type 6 principally in Hong Kong and Southeast Asia [137,153]. Mixed genotype infections from a major and a minor HCV population accounts for 4-17% of HCV patients [154].
4.4. Effect of genotype on disease severity
In recent years, substantial evidence has emerged indicating the role of HCV genotypes in disease severity and sensitivity to the antiviral therapy [140,146]. Importantly, patients infected with any of the 6 genotype can develop advanced liver disease, including cirrhosis and HCC. However, some genotypes appear to be more severe compared to the other. For example, Chronic HCV patients infected with genotype 1b is reported to be associated with a more severe liver disease and a more aggressive course compared to genotype 2 (146,155-157]. HCV genotype 1b has also been reported to be associated with the development of advanced liver disease including cirrhosis and hepatocellular carcinoma (HCC) compared to other genotypes (157,158]. However, other investigators failed to arrive at the same conclusions for genotype 1b and therefore further studies are required to elucidate any role of HCV genotype in disease progression or severity [159-162]. A study from India, indicate that most of the chronic hepatitis patients related to genotype 3 is associated with significant steatosis (accumulation of fat within hepatocytes) and fibrosis [163]. Another study report steatosis regardless of genotypes, but resolution of viral infection from genotype 3a patients is associated with disappearance of steatosis and hence genotype 3a and steatosis are interlinked [164]. According to latest statistics 15% of Egyptians are infected with HCV and most of these patients have genotype 4 [165,166]. Genotype 4 has also been associated with a severe disease and increased development of HCC [165]. HCV Genotype 5 is associated with higher mean age compared to other HCV genotype infection [167]. Report from Hong Kong suggested prominence of genotype 6 in patients with thalassemia major and intravenous drug abusers [168].
4.5. HCV genotype and antiviral treatment response
The main objective of therapy administered to patients with chronic hepatitis C is to achieve a Sustained Virological Response (SVR). SVR is characterized by the clearance of serum HCV RNA at the end of therapy and maintained throughout the 6-month follow up period after completion of treatment [169]. The current treatment for HCV infection is two daily doses of ribavirin (non-specific anti-viral agent) combined with a weekly injection of interferon-α (standard or pegylated) [170]. The recommended treatment length depends on the virus genotype. Patients with genotypes 2 and 3 are almost three times more likely than patients with genotype 1 to respond to the combination of alpha interferon and ribavirin therapy [129, 164, 171, 172]. Notably, patients with genotype 2 and 3, a 24 week course of combination treatment is adequate, whereas a 48 week course is recommended for genotype 1 [172]. Although, the response of combination therapy against genotype 2 and 3 is better, still there are moderately high percentage of non-responders. The re-treatment response involving combination therapy in non-responders are still better in genotype 2 and 3 (50-60% SVR) compare to genotype 1 (14%) [173]. Genotype 4 presents advance liver disease in patients, and response to Interferon-Ribavirin combination therapy is moderate with ~60% SVR after 48 weeks treatment [174]. Similarly, among genotype 5 patients, the response rate achieved is more than 60% SVR, when treated with Interferon-Ribavirin combination therapy for 48 weeks [175]. HCV genotype 6 responds better to Interferon-Ribavirin combination therapy compare to genotype 1 with treatment duration of 48 weeks [176].
5. Hepatitis D virus
HDV was first discovered in 1977 among a group of patients infected with hepatitis B virus [177]. HDV depends on the HBV to provide hepatitis B surface antigen (HBsAg) for virion assembly and propagation [178]. There are approximately 350 million chronic HBV carriers of the virus, according to the available data 5% (15 million) of these HBV carriers are infected with HDV [179,180]. HDV is highly endemic in Mediterranean countries, Middle East, Central Africa, and northern parts of South America [181]. In contrast, in industrialized countries, its prevalence is low and its transmission is often associated with intravenous drug use [182]. HDV is transmitted through blood and body fluids, quite similar to that of HBV [183]. Hepatitis D symptoms are identical to other viral hepatitis diseases and include jaundice, fever, malaise, dark urine and nausea [183].
5.1. Disease severity
HDV propagates in human hepatocytes as its natural host but only in presence of hepatitis B virus, causing severe acute, fulminant or chronic hepatitis leading to liver cirrhosis [179, 184, 185]. HDV infection can occur either as a co-infection with HBV or as a superinfection in patients with chronic HBV infection [179]. The individuals with HBV-HDV co-infection resulted in more severe acute disease and a higher risk of fulminant hepatitis than HBV alone (1983). Only 2% of co-infected patients resulted in chronic infection [186]. Super infection with HDV in HBV chronic carriers leads to higher incidence of cirrhosis and hepatocellular carcinoma [187]. A factor that may influence the course of disease is the genetic heterogeneity of HDV prevalent in different geographical areas [188].
5.2. Genome organization
The HDV virion is a spherical particle of about 36-nm in diameter, which contains an envelope (HBsAg) and a nucleocapsid containing an RNA genome in complex with HDAg [189-191]. HDV particles consist of a negative sense, circular, single-strand RNA genome, approximately 1.7 kb in length. HDV anti-genome contains a unique open reading frame that encodes the small (sHD) and large hepatitis delta (LHD) proteins. The sHD and LHD correspond respectively to the small-p24 and the large-p27 hepatitis delta proteins [192]. The LHD amino acid sequence is identical to sHD except with the extension of 19 to 20 amino acids at carboxy-terminal end [192, 193]. sHD is required for viral replication and might promote RNA polymerase II elongation of nascent HDV RNA, while LHD inhibits HDV RNA replication and is required for HDV RNA packaging with the HBV envelope protein [194].
5.3. HDV genotypes and geographic distribution
To date researchers have identified 8 major clades or genotypes of hepatitis delta virus based on phylogenetic analysis and are labeled as HDV-1 to HDV-8 [195]. These genotypes are mostly defined based on the analysis of 357 nucleotide semi-conserved region of HDV genome [187,196,197] (Fig. 10).The sequence differences among these genotypes are significant; there is a divergence of 40% in nucleotide sequence and 35% in amino acid sequence of HDAg. Distribution of genotype 1 is ubiquitous which includes European, North American, African, and some Asian isolates [187,196-199]. Genotype 2 has been found in Japan, Taiwan and Yakoutia (Russia) [200]. Genotype 3 has been found exclusively in Central and South America [187]. Genotype 4 was mostly prevalent in Japan and Taiwan [200,201]. Genotype 5-8 has been exclusively found in Africa [195] (Fig. 11).
5.4. Effect of genotype on disease severity
The genetic variant of hepatitis D virus along with geographical location and transmission route have been identified as important determinants of disease severity [202,203]. At one geographic location genotype 1 has been associated with fulminant hepatitis and hepatocellular carcinoma [196], while in other locality the same genotype have a mild clinical course [197,199]. The diversity observed among genotype HDV-2 has been associated with a less aggressive course, lower ALT values and HDV RNA levels than genotype HDV-1[196,204]. Genotype HDV-3 is endemic in northern South America and is associated with a severe clinical course [184]. Genotype HDV-4 (previously labeled HDV-IIb) also showed variable severity depending upon the geographic location [200,201,205]. Genotype HDV (5-8), mostly observed in African patients, most patients suffered from active chronic hepatitis or cirrhosis [181,195].
5.5. HDV Genotype and antiviral treatment response
There is no specific treatment for HDV infection. Treatment of chronic delta hepatitis is not very effective using long-term administration of high doses of interferon-alpha [206]. It is not known whether some HDV genotypes might be more susceptible to therapy than others. Although, there is no specific vaccine for HDV but vaccination of persons at high risk of acquiring HBV will prevent the acquisition of HDV infection.
6. Hepatitis E virus
HEV infection is a significant public health problem in many parts of the world, especially in developing countries [207-209]. It is estimated that about 2 billion people live in areas endemic for HEV [207,208]. HEV is transmitted via the fecal-oral route and target population includes young to middle aged adults [210]. Patients infected with HEV present with nausea, vomiting, anorexia, jaundice, abdominal pain, fever, and hepatomegaly [211]. It causes large outbreaks of acute hepatitis but usually resolves without any therapy [212-214]. The infected individual therefore develops antibodies that protect against future infection.
6.1. Disease severity
The clinical presentation of this disease ranges from subclinical to fulminant hepatic failure [215,216]. HEV is a major cause of fulminant hepatitis in endemic areas such as India and Bangladesh [216]. Hepatitis E has a mortality rate of 1-4% in the general population [211]. Increased morbidity and mortality is observed in chronic liver disease patients superinfected with HEV [215]. The endemic area is frequently associated with increased incidence and severity in pregnant women with around 15-20% mortality rate [217]. More than one-fourth of affected women have obstetric complications, such as premature rupture of membranes and intrauterine growth restriction [218,219]. It is unknown why HEV causes severe disease in pregnant women.
6.2. Genome organization
HEV is a spherical, non-enveloped virus of about 27–34 nm, classified currently as the sole member of the genus
6.3. HEV genotypes and geographic distribution
Four major genotypes (genotypes 1-4) of mammalian HEV have been identified on the basis of complete genome sequences [229,230]. Recently, partial sequence of HEV conserved region (i.e. ORF1 and ORF2) reflects nucleotide sequence heterogeneity and hence genotyping of HEV is possible without determining the entire genomic sequence [231,232] (Fig. 13). Regions within nucleotides 171–221, 280–310 and 6461–6495 were most conserved and represented the best targets for primer or probe design for genotyping and quantitation [232].
Genotype 1 is mostly prevalent in Asia and Africa [230,233,234]. Genotype 2 is found in Central and South America as well in African countries (Fig. 14). Both genotype 1 and 2 outbreaks are the result of efficient human-to-human feco-oral transmission mostly in developing countries [231,234]. In industrialized countries, HEV genotype 1 infection is rare, therefore its presence there is treated as imported infectious disease [231]. Genotype 3 includes human and swine HEV strains from industrialized countries [235,236]. Finally, genotype 4 includes human and swine HEV strains from Asia, particularly China, Taiwan and Japan [234,237]. HEV strains of genotype 3 and 4 are maintained among animal species and occasionally infect humans probably due to inefficient cross-species transmission [235].
6.4. Genotype variations and disease severity
The severity of HEV associated acute hepatitis not only depends on the status of the host’s immune system but also on viral factors such as genotypes. Hepatitis outbreaks in developing countries have been caused primarily by HEV genotype 1. Most of the patients suffering from hepatitis E caused by genotypes 1 are older children and young adults with mortality rate 1%[231,238]. A study from India reported that the viral load of genotype 1was significantly higher in pregnant patients than in non-pregnant patients, and high viral load might be a reason for severe liver disease in pregnant patients [239]. Genotype 2 is Mexican origin and mostly prevalent in central American and African countries, like genotype 1, it is mostly self-limiting. HEV genotype 3 is prevalent in industrialized nations and is rarely pathogenic. Recently, it has been reported that genotype 4 infected patients showed more severe form of the viral hepatitis than genotype 3 [240,241].
Most of the patients in this group belong to older age (~60 years) and the mortality rate is relatively high (6-10%) [231,242]. Japanese study suggested that the silent substitutions of U3148 and C5907 in the genotype 3 and 4 HEV strains are closely associated with the occurrence of fulminant and severe cases and found that C5907 is associated with high HEV load [243]. Thus, the genetic changes in hepatitis E virus genome may affect the effectiveness of virus transmission and hence the severity of HEV-associated hepatitis. Therefore, examination of HEV genotype is considered necessary in order to predict the clinical course and the outcome.
6.5. HEV genotype and antiviral treatment response
Since most of the cases are self-limiting, acute HEV does not require antiviral therapy in immunocompetent patients related to any genotype. The immunosuppressed patients should be recommended ribavirin, so that these patients should not progressed to cirrhosis. Liver transplantation is the only treatment option for patients with fulminant hepatic failure due to HEV. All the four mammalian HEV strains belong to one serotype. Thus, only one hepatitis E vaccine is needed for broad protection. The first phase of the immunoprophylaxis of HEV is already tested for safety and immunogenicity [244]. The next phase is to make it available in the market, especially in developing countries so that it should be effectively controlled.
7. Conclusions
The analysis of genomic sequence heterogeneity among different isolates of hepatitis viruses (A-E) may provide an opportunity to decipher the course and pathogenesis of the virus. Although, lot of information are available in this area but still there are many contradictions and discrepancies.
Therefore, the genomic heterogeneity of hepatitis viruses is not the only critical factor that leads to disease progression, severity and final outcome. Hence, in combination with viral genomic heterogeneity other factors such as age, sex, geographical distribution, genetic polymorphism and host immune elements may play a vital role in deciding the clinical implications and final outcome of the infection.
References
- 1.
A: detection by immune electron microscopy of a virus like antigen associated with acute illness.Feinstone S M Kapikian A, Z Purcell R, H 1973 Hepatitis Science, 182, 1026 - 2.
World Health Organization 2000 Hepatitis A vaccines.Wkly Epidemiol Rec 75 38 44 - 3.
W. (Craig A S Schaffner 2004 Prevention of hepatitis A with the hepatitis A vaccine.N Engl J Med 350 476 481 - 4.
A in the era of vaccination.Wasley A Fiore A Bell B P 2006 Hepatitis Epidemiol Rev. 28 101 111 - 5.
A virus seroprevalence by age and world region, 1990 and 2005.Jacobsen K H Wiersma S, T 2010 Hepatitis Vaccine 28 6653 6657 - 6.
1996 Hepatitis A Epidemiology and prevention.Feinstone S.M. Eur J Gastroenterol Hepatol 8 300 5 - 7.
M, C. (Marinho R T Valente A, R Ramalho F,J De Moura 1997 The changing epidemiological pattern of hepatitis A in Lisbon, Portugal.Eur J Gastroenterol Hepatol 9 795 797 - 8.
Hussain Z Das B C Husain S, A Murthy N, S Kar 2006 Increasing trend of acute hepatitis A in north India: need for identification of high-risk population for vaccination.J Gastroenterol Hepatol 21 , 689-693 - 9.
S, S. (Arankalle V A Chadha M, S Chitambar S, D Walimbe A, M Chobe L, P Gandhe 2001 Changing epidemiology of hepatitis A and E in urban and rural India (1982-1998).J Viral Hepat 8 293 303 - 10.
1996 Hepatitis A VirusHollinger F. B Ticehurst J.R. Fields Virology , 3rded.; Fields, B.N., Knipe, D.M., Howley, O.M.,et al. Eds.; Lippincott Williams & Wilkins: Philadelphia, NY, USA,735 782 - 11.
Debray D Cullufi P Devictor D Fabre M Bernard O 1997 Liver failure in children with hepatitis A.Hepatology 26 1018 1022 - 12.
Koff R S 1998 Hepatitis A Lancet 351 1643 1649 - 13.
R. (O Grady J, G Schalm S,W Williams 1993 Acute liver failure: redefining the syndromes.Lancet ,342 273 275 - 14.
Takashaki Y Okuda K 1993 Fulminant and subfulminant hepatitis in Japan.Indian J Gastroenterol 12 19 21 - 15.
Acharya S K Dasarathy T,L.S Kumer et al 1996 Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome.Hepatology, 23 1448 1455 - 16.
B. (Keeffe E 1995 Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver disease?Am J Gastroenterol 90 201 205 - 17.
Vento S Garofano T Rezzini C Cainelli F Casali F Ghirozi G Ferraro T Concai E 1998 Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic C.N Engl J Med ,29 286 290 - 18.
Najarian R Caput D Gee W et al 1985 Primary structure and gene organization of human hepatitis A virus.Proc. Natl. Acad. Sci. USA 82 2627 2631 - 19.
K, M.Borman A M Kean 1997 Intact eukaryotic initiation factor 4G is required for hepatitis A virus internal initiation of translation.Virology 237 129 136 - 20.
Totsuka A Moritsugu Y 1999 Hepatitis A virus proteins.Intervirology 42 63 68 - 21.
S, M. (Chang K H Brown E, A Lemon 1993 Cell type specific proteins which interact with the 5) non translated region of hepatitis A virus RNA.J Virol 67 6716 6725 - 22.
C of hepatitis A virus (HAV) cleaves the HAV polyproteinSchultheiss T Kusov Y Y Gauss-muller V 1994 Proteinase 2 P3 at all sites including VP1/2A and 2A/2B.Virology198 , 275-281 - 23.
Cohen J. I Ticehurst J. R Purcell R. H Buckler-white A Baroudy B. M 1987 Complete nucleotide sequence of wild type hepatitis A virus: comparision with different strains of hepatitis A virus and other picornaviruses.J Virol 61 50 59 - 24.
Arauz-ruiz P L Sundqvist Z Garcia L Taylor K Visona andH Norder L. O Magnius 2001 Presumed common source outbreaks of hepatitis A in an endemic area confirmed by limited sequencing within the VP1 region.J Med Virol 65 449 456 - 25.
Costa-mattioli M Cristina J Romero H et al 2002 Molecular evolution of hepatitis A virus: a new classification based on the complete VP1 protein.J Virol 76 9516 9525 - 26.
Khanna B Spelbring J. E Innis B. L Robertson B. H 1992 Characterization of a genetic variant of human hepatitis A virus.J Med Virol 36 118 124 - 27.
Robertson B. H Jansen R. W Khanna B et al 1992 Genetic relatedness of hepatitis A virus strains recovered from different geographical regions.J Gen Virol 73 1365 1377 - 28.
Ching K. Z Nakano T Chapman L. E Demby A Robertson B. H 2002 Genetic characterization of wild-type genotype VII hepatitis A virus.J Gen Virol 83 53 60 - 29.
Jansen R. W andG Siegl S. M Lemon 1990 Molecular epidemiology of human hepatitis A virus defined by an antigen-capture polymerase chain reaction method.Proc. Natl. Acad. Sci. USA 87 2867 2871 - 30.
Di Napoli, A., Ferre, V., Billaudel, S., Perez-Bercoff, R., Cristina, J.Costa-mattioli M 2003 Genetic variability of hepatitis A virus.J Gen Virol 84 3191 3201 - 31.
Hussain Z Das B. C Husain S. A et al 2005 Hepatitis A viral genotypes and clinical relevance: Clinical and molecular characterization of hepatitis A virus isolates from northern India.Hepatol Res 32 16 24 - 32.
Fujiwara K Yokosuka O Ehata T et al 2002 Association between severity of type A hepatitis and nucleotide variations in the 5’ non-translated region of hepatitis A virus RNA: strains from fulminant hepatitis have fewer nucleotide substitutions.Gut 5 82 88 - 33.
Kanda T Jeong S. H Imazeki F Fujiwara K Yokosuka O 2010 Analysis of 5’ non-translated region of hepatitis A viral RNA genotype I from South Korea: comparison with disease severities.PLoS One 5, e15139 - 34.
Fujiwara K Yokosuka O Imazeki F et al 2003 Analysis of the genotype determining region of hepatitis A viral RNA in relation to disease severities.Hepatol Res 25 124 134 - 35.
Rezende G Roque-afonso A. M Samuel D et al 2003 Viral and clinical factors associated with the fulminant course of hepatitis A infection.Hepatology 38 613 618 - 36.
Normann A Jung C Vallbracht A Flehmig B 2004 Time course of hepatitis A viremia and viral load in the blood of human hepatitis A patients.J Med Virol 72 10 16 - 37.
van den Hoek A et al. (Tjon G. M Coutinho R. A 2006 High and persistent excretion of hepatitis A virus in immunocompetent patients.J Med Virol 78 1398 1405 - 38.
Yoon Y. K Yeon J. E Kim J. H et al 2011 Comparative analysis of disease severity between genotypes IA and IIIA of hepatitis A virus.J Med Virol 83 1308 1314 - 39.
Coppola N Genovese D Pisaturo M et al 2007 Acute hepatitis with severe cholestasis and prolonged clinical course due to hepatitis A virus Ia and Ib coinfection.Clin Infect Dis 44, e73 e77 - 40.
Tiollais P Pourcel C Dejean A 1985 The hepatitis B virus.Nature 317 489 495 - 41.
Zuckerman A. J 1996 Hepatitis viruses. In Baron S,et al. .Baron’s Medical Microbiology (4th ed.). University of Texas Medical Branch - 42.
Tibbs C. J Smith H. M 2001 Clinicians guide to viral hepatitis. 1st Edition. Arnold - 43.
Kao J. H Chen D. S 2002 Global control of hepatitis B virus infection.Lancet Infect Dis 2 395 403 - 44.
Hou J Liu Z Gu F 2005 Epidemiology and Prevention of Hepatitis B Virus Infection.International Journal of Medical Sciences 2 50 57 - 45.
Lee W. M 1997 Hepatitis B virus infection.N Engl J Med 337 1733 1745 - 46.
Alter M. J 2003 Epidemiology and prevention of hepatitis B.Semin liver Dis 23 39 46 - 47.
Gust I Crowe S 1986 The global importance of viral hepatitis. Clin Trop Med Commun Dis1 281 301 - 48.
Custer B Sullivan S. D Hazlet T. K Iloeje U Veenstra D. L Kowdley K. V 2004 Global epidemiology of hepatitis B virus.J Clin Gastroenterol 38, S158 S168 - 49.
Kidd-ljunggren K Myhre E Bläckberg J 2004 Clinical and serological variation between patients infected with different Hepatitis B virus genotypes.J Clin Microbiol 42 5837 5841 - 50.
Kao J. H 2003 Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan.Intervirology 46 400 407 - 51.
Fattovich G Stroffolini T Zagni I Donato F 2004 Hepatocellular carcinoma in cirrhosis: incidence and risk factors.Gastroenterology 127, S35 50 - 52.
Locarnini S. A 2002 Clinical relevance of viral dynamics and genotypes in hepatitis B virus.Journal of Gastroenterology & Hepatology 17, S322 S328 - 53.
Lavanchy D 2004 Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.Journal of Viral Hepatitis 11 97 107 - 54.
Summers J Mason W. S 1982 Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate.Cell 29 403 415 - 55.
Locarnini S 2004 Molecular virology of hepatitis B virus.Semin Liver Dis 24 3 10 - 56.
Beck J Nassal M 2007 Hepatitis B virus replication.World J Gastroenterol 13 48 64 - 57.
Jilbert A. R Burrell C. J Triatni M Kann M 2002 Hepatitis B virus replication. InHepatitis B Virus, 43 Edited by Lai C-L & Locarnini S. London: International Medical Press53 - 58.
Seeger C & Mason WS 2000 Hepatitis B virus biology.Microbiology & Molecular Biology Reviews 64 51 68 - 59.
Wu H. L Huang L. R Huang C. C et al 2005 RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant.Gastroenterology 128 708 716 - 60.
Okamoto H Tsuda F Sakugawa H Sastrosoewignjo R. I Imai M Miyakawa Y Mayumi M 1988 Typing hepatitis B virus by homology in nucleotide sequence: Comparison of surface antigen subtypes. J Gen Virol 69 2575 2583 - 61.
Cao G. W 2009 Clinical relevance and public health significance of hepatitis B virus genomic variations.World J Gastroenterol 15 5761 5769 - 62.
Mcmahon B. J 2009 The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B.Hepatol Int 3 334 42 - 63.
Kurbanov F Tanaka Y Mizokami M 2010 Geographical and genetic diversity of the human hepatitis B virus.Hepatol Res 40 14 30 - 64.
Lin C. L Kao J. H 2011 The clinical implications of hepatitis B virus genotype: Recent advances.J Gastroenterol Hepatol 1 123 30 - 65.
Kao J. H 2002 Clinical relevance of hepatitis B viral genotypes: a case of deja vu?Journal of Gastroenterology & Hepatology 17 113 115 - 66.
Locarnini S & Magnius LO. (Norder H Courouce A. M Coursaget P Echevarria J. M Lee S. D Mushahwar I. K Robertson B. H 2004 Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.Intervirology 47 289 309 - 67.
Magnius LO & Norder H 1995 Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene.Intervirology 38 24 34 - 68.
Mahtab M. A Rahman S Khan M Karim F 2008 Hepatitis B virus genotypes: an overview. Hepatobiliary Pancreat Dis Int 7 457 464 - 69.
Alvarado Mora MV, Romano CM, Gomes-Gouvea MS, Gutierrez MF, Botelho L, Carrilho FJ, Pinho JRR. (2011 Molecular characterization of the Hepatitis B virus genotypes in Colombia: A Bayesian inferences on the genotype F.Infection, genetics and Evolution 11 103 108 - 70.
Stuyver L De Gendt S Van Geyt C Zoulim F Fried M Schinazi R. F Rossau R 2000 A new genotype of hepatitis B virus: completegenome and phylogenetic relatedness.J Gen Virol 81 67 74 - 71.
B virus genotype assignment using restriction fragment length polymorphism patterns.Mizokamia M Nakanob T Oritob E Tanakab Y Sakugawac H Mukaided M H Robertsone B 1999 Hepatitis FEBS Letters 450 66 71 - 72.
Grandjacques C Pradat P Stuyver L Chevallier M Chevallier P Pichoud C Maisonnas M Trepo C Zoulim F 2000 Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity.J Hepatol 33 430 439 - 73.
Naito H Havashi S Abe K 2001 Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers.J Clin Microbiol 39, 1686 - 74.
Chu C. J Keeffe E. B Han S. H Perrillo R. P Min A. D Soldevila-pico C et al 2003 Hepatitis B virus genotypes in the United States: results of a nationwide study.Gastroenterology 125 444 451 - 75.
Kumar A Kumar S. I Pandey R Naik S Aggarwal R 2005 Hepatitis B virus genotype A is more often associated with severe liver disease in northern India than is genotype D. Indian J Gastroenterol 24 19 22 - 76.
Sugauchi F Orito E Ichida T Kato H Sakugawa H Kakumu S Ishida T Chutaputti A Lai C. L Ueda R Miyakawa Y Mizokami M 2002 Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene.J Virol 76 5985 5992 - 77.
Lin C. L Chen J. D Liu C. J et al 2007 Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma.J Viral Hepat 2007;14 64 69 - 78.
Zhang H. W Yin J. H Li Y. T et al 2008 Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China.Gut 57 1713 1720 - 79.
Matsuura K Tanaka Y Hige S et al 2009 Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A.J Clin Microbiol 47 1476 1483 - 80.
Padbidri VS & Sehgal SC. (Arankalle V. A Murhekar K. M Gandhe S. S Murhekar M. V Ramdasi A. Y 2003 Hepatitis B virus: predominance of genotype D in primitive tribes of the Andaman and Nicobar islands, India (1989-1999).J Gen Virol 84 1915 1920 - 81.
Chattopadhyay S Das B. C Hussain Z Kar P 2006 Hepatitis B virus genotypes in acute and fulminant hepatitis patients from north India using two different molecular genotyping approaches.Hepatol Res 35 79 82 - 82.
Abdo A. A Al-jarallah B. M Sanai F. M Hersi A. S Al-swat K Azzam N. A Al-dukhayil M Al-maarik A Al-faleh F. Z 2006 Hepatitis B genotypes: relation to clinical outcome in patients with chronic hepatitis B in Saudi Arabia.World J Gastroenterol 12 7019 7024 - 83.
Bruguera M & Rodes J. (Sanchez-tapias J. M Costa J Mas A 2002 Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.Gastroenterology 123 1848 1856 - 84.
Pineiro YLFG Mbayed VA and Campos RH. (2003 Evolutionary history of hepatitis B virus genotype F: an in-depth analysis of argentine isolates.Virus Genes 27 103 110 - 85.
Ueda R & Mizokami M. (Suzuki S Sugauchi F Orito E Kato H Usuda S Siransy L Arita I Sakamoto Y El-Yoshihara N Gohary A 2003 Distribution of hepatitis B virus (HBV) genotypes among HBV carriers in the Cote d’Ivoire: complete genome sequence and phylogenetic relatedness of HBV genotype E.J Med Virol 69 459 465 - 86.
Arauz-Ruiz, Norder PH, Robertson BH, Magnius LO, Genotype H. (2002 A new Amerindian genotype of hepatitis B virus revealed in Central America.J Gen Virol 83 2059 2073 - 87.
Miyakawa Y& Mizokami M. (Kato H Gish R. G Bzowej N Newsom M Sugauchi F Tanaka Y Kato T Orito E Usuda S Ueda R 2004 Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics.J Med Virol 73 516 521 - 88.
Devesa M Loureiro C. L Rivas Y Monsalve F Cardona N Duarte M. C Poblete F Gutierrez M. F Botto C Pujol F. H 2008 Subgenotype diversity of hepatitis B virus American genotype F in Amerindians from Venezuela and the general population of Colombia.J Med Virol 80 20 26 - 89.
C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam-genotypes B4 and C1 predominate.Thuy P. T Alestig E Liem N. T Hannoun C Lindh M 2010 Genotype X J Med Virol 82 1327 1333 - 90.
Tatematsu K Tanaka Y Kurbanov F et al 2009 A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J.J Virol 83 10538 47 - 91.
Sumi H Yokosuka O Seki N Arai M Imazeki F Kurihara T et al 2003 Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease.Hepatology 37 19 26 - 92.
Suzuki Y Kobayashi M Ikeda K et al 2005 Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan.J MedVirol 76 33 39 - 93.
Kao J. H Chen P. J Lai M. Y Chen D. S 2000 Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.Gastroenterology 118 554 559 - 94.
Thakur V Guptan R. C Kazim S. N Malhotra V Sarin S. K 2002 Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent.J Gastroenterol Hepatol 17 165 70 - 95.
Lindh M Hannoun C Dhillon A. P Norkrans G Horal P 1999 Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers.J Infect Dis 179 775 782 - 96.
Chan H. L Hui A. Y Wong M. L et al 2004 Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.Gut 53 1494 1498 - 97.
Yuen M. F Sablon E Wong D. K Yuan H. J Wong B. C Chan A. O Lai C. L 2003 Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation.Clin Infect Dis 37 593 597 - 98.
Orito E Ichida T Sakugawa H Sata M Horiike N Hino K Okita K Okanoue T Iino S Tanaka E Suzuki K Watanabe H Hige S Mizokami M 2001 Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan.Hepatology 34 590 594 - 99.
Chen Y. C Sheen I. S Chu C. M Liaw Y. F 2002 Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.Gastroenterology 123 1084 1089 - 100.
Hsu Y. S Chien R. N Yeh C. T et al 2002 Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.Hepatology 35 1522 1527 - 101.
Kao J. H Chen P. J Lai M. Y Chen D. S 2004 Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers.J Med Virol 72 363 369 - 102.
Wai C. T Fontana R. J Polson J et al 2005 Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States.J Viral Hepatol 12 192 198 - 103.
Yuen M. F Wong D. K Sablon E et al 2004 HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.Hepatology 39 1694 1701 - 104.
Imamura T Yokosuka O Kurihara T Kanda T Fukai K Imazeki F Saisho H 2003 Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan.Gut 52 1630 1637 - 105.
Yuen M. F Tanaka Y Mizokami M et al 2004 Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study.Carcinogenesis 25 1593 1598 - 106.
Sharma S Sharma B Singla B et al 2010 Clinical significance of genotypes and precore/basal core promoter mutations in HBV related chronic liver disease patients in North India.Dig Dis Sci 55 794 802 - 107.
Liu S Zhang H Gu C et al 2009 Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis.J Natl Cancer Inst 101 1066 82 - 108.
Fan Y. F Lu C. C Chen W. C et al 2001 Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection.Hepatology 33 277 286 - 109.
Sugauchi F Ohno T Orito E et al 2003 Influence of hepatitis B virus genotypes on the development of pre-S deletions and advanced liver disease.J Med Virol 70 537 544 - 110.
Lin C. L Liu C. H Wendy C et al 2007 Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma.J Gastroenterol Hepatol 22 1098 1103 - 111.
Liu C. J Kao J. H Chen D. S 2005 Therapeutic implications of hepatitis B virus genotypes.Liver Int 25 1097 1107 - 112.
Liu C. J Kao J. H 2008 Genetic variability of hepatitis B virus and response to antiviral therapy.Antivir Ther 13 613 624 - 113.
Kao J. H Wu N. H Chen P. J Lai M. Y Chen D. S 2000 Hepatitis B genotypes and the response to interferon therapy.J Hepatol 33 998 1002 - 114.
Janssen HLA. (Hou J Schilling R 2001 Molecular characteristics of hepatitis B virus genotype A confer a higher response to interferon treatment.J Hepatol 34, 15 - 115.
Wai C. T Chu C. J Hussain M Lok A. S 2002 HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.Hepatology 36 1425 1430 - 116.
Erhardt A Blondin D Hauck K et al 2005 Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.Gut 54 1009 1013 - 117.
Buti M Cotrina M Valdes A Jardi R Rodriguez-frias F Esteban R 2002 Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?J Hepatol 36 445 446 - 118.
Yuen M. F Wong D. K Sablon E et al 2003 Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine.Antivir Ther 8 531 534 - 119.
Choo Q. L Kuo G Weiner A. J Overby L. R Bradley D. W Houghton M 1989 Isolation of acDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.Science 244 359 362 - 120.
Choo Q. L Richman K. H Han J. H et al 1991 Genetic organization and diversity of the hepatitis C virus.Proc Natl Acad Sci USA 88 2451 2455 - 121.
Van Der Poel C. L Reesink H. W Lelie P. N Leentvaar-kuypers A Choo Q. L Kuo G Houghton M 1989 Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands.Lancet 2 297 298 - 122.
Saeed A. A Al-admawi A. M Al-rasheed A Fairclough D Bacchus R Ring C Garson J 1991 Hepatitis C virus infection in Egyptian volunteer blood donors in Riyadh.Lancet 338 459 460 - 123.
Maheshwari A; Ray S; Thuluvath PJ. (2008 Acute hepatitis C.Lancet 372 321 332 - 124.
Rosen H. R 2011 Clinical practice. Chronic hepatitis C infection.N Engl J Med 364 2429 2438 - 125.
Hoofnagle J. H 2002 Course and outcome of hepatitis C.Hepatology 36, S21 S29 - 126.
Alter M. J Margolis H. S Krawczynski K et al 1992 The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties chronic non-A, non-B Hepatitis Study Team.N Engl J Med 327 1899 1905 - 127.
Fattovich G Giustina G Degos F et al 1997 Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).J Hepatol 27 201 205 - 128.
Seeff LB & Hoofnagle JH 2003 Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.Clinical Liver Disease 7 261 287 - 129.
Ratziu V & Lai CL. (Poynard T Yuen M. F 2003 Viral hepatitis C. Lancet 362 2095 2100 - 130.
Maynard M & Trepo C. (Zoulim F Chevallier M 2003 Clinical consequences of hepatitis C virus infection.Rev MedVirol 13 57 68 - 131.
Takamizawa A. C Mori I Fuke S 1991 Structure and organization of the hepatitis C virus genome isolated from human carriers.J Virol 65 1105 1113 - 132.
Kato N 2000 Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation.Microb Comp Genomics 5 129 151 - 133.
Houghton M Weiner A Han J Kuo G Choo Q. L 1991 Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease.Hepatology 14 381 388 - 134.
Weiner A. J Brauer M. J Rosenblatt J et al 1991 Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1proteins and the pestivirus envelope glycoproteins.Virology 180 842 848 - 135.
Tsukiyama-kohara K Iizuka N Kohara M Nomoto A 1992 Internal ribosome entry site within hepatitis C virus RNA.J Virol 66 1476 1483 - 136.
Ogata N H. J Alter andR. H Miller R. H Purcell 1991 Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.Proc Natl Acad Sci USA 88 3392 3396 - 137.
Simmonds P Holmes E. C Cha T. A et al 1993 Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region.J Gen Virol 74 2391 2399 - 138.
Hoofnagle J. H 2002 Course and outcome of hepatitis C.Hepatology 36, S21 S29 - 139.
Franco S Gimenez-barcons M Puig-basagoiti F et al 2003 Characterization and evolution of NS5A quasispecies of hepatitis C virus genotype 1b in patients with different stages of liver disease.J Med Virol 71 195 204 - 140.
Simmonds P 1995 Variability of hepatitis C virus.Hepatology 21 570 583 - 141.
Robertson B Meyers G Howard C et al 1998 Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization.Arch Virol 43 2493 503 - 142.
andXavier F J Bukh 1998 Methods for determining the hepatitis C genotype.Viral Hepatitis Rev 4 1 19 - 143.
Stuyver L R Rossau A Wyseur M Duhamel B Vanderborght andH Van Heuverswyn G Maertens 1993 Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay.J Gen Virol 74 1093 1102 - 144.
et al. (Okamoto H Y Sugiyama S Okada 1992 Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources.J Gen Virol 73 673 679 - 145.
andZein N. N D. H Persing 1996 Hepatitis C genotypes: current trends and future implications.Mayo Clin Proc 71 458 462 - 146.
Zein N. N 2000 Clinical significance of hepatitis C virus genotypes.Clinical Microbiology Reviews 13 223 235 - 147.
Pawlotsky J. M 2003 Hepatitis C virus genetic variability: pathogenic and clinical implications.Clinical Liver Disease 7 45 66 - 148.
Nousbaum J. B Pol S Nalpas B Landais P Berthelot P Bréchot C 1995 Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.Ann Intern Med 122 161 168 - 149.
Takada N S Takase andA Takada T Date 1993 Differences in the hepatitis C virus genotypes in different countries.J Hepatol 17 277 283 - 150.
Pawlotsky J. M L Taskiris F Roudot-thoraval C Pellet L Stuyver andJ Duval D Dhumeaux 1995 Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.J Infect Dis 171 1607 1610 - 151.
Chamberlain R. W N Adams A. A Saeed andP Simmonds R. M Elliott 1997 Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East.J Gen Virol 78 1341 1347 - 152.
Agha S Tanaka Y Saudy N et al 2004 Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: A collaborative study between Japan, Egypt, and Uzbekistan.J Med Virol 73 216 222 - 153.
Cha T. A E Beall B Irvine J Kolberg D Chien andG Kuo M. S Urdea 1992 At least five related, but distinct, hepatitis C viral genotypes exist.Proc Natl Acad Sci USA 89 7144 7148 - 154.
Blatt L. M Mutchnick M. G Tong M. J et al 2000 Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in United States.J Viral Hepat 7 196 202 - 155.
Bruno S Silini E Crosignani A et al 1997 Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study.Hepatology 25 754 758 - 156.
Tassopoulos N. C Papatheodoridis G. V Katsoulidou A et al 1998 Factors associated with severity and disease progression in chronic hepatitis C.Hepatogastroenterology 45 1678 1683 - 157.
Lee C. M Hung C. H Lu S. N et al 2006 Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan.Intervirology 49 76 81 - 158.
De Mitri M. S Poussin K Baccarini P et al 1995 HCV-associated liver cancer without cirrhosis.Lancet 345 413 415 - 159.
Johnson PJ & Williams R. (Naoumov N. V Chokshi S Metivier E Maertens G 1997 Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis.J Hepatol 27 331 336 - 160.
Dienstag JL & Liang TJ. (Reid A. E Koziel M. J Aiza I Jeffers L Reddy R Schiff E Lau J. Y 1999 Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States.Am J Gastroenterol 94 1619 1626 - 161.
Genotype b and severity of posttransplant recurrence of hepatitis C infection-unconvictable felon or wrongly accused?Charlton M 2000 Liver Transplantation 6 243 245 - 162.
del Olmo JA, Escudero A &Rodrigo JM. (Serra M. A Rodriguez F 2003 Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage.J Viral Hepat 10 183 188 - 163.
Hissar S. S Goyal A Kumar M et al 2006 Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease.J Med Virol 78 452 458 - 164.
Adinolfi L. E Gambardella M Andreana A Tripodi M. F Utili R Ruggiero G 2001 Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.Hepatology 33 1358 1364 - 165.
Zekri A. R Bahnassy A. A Shaarawy S. M Mansour O. A Maduar M. A El-Khaled H. M Ahmadi O 2000 Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma.J Med Microbiol 49 89 95 - 166.
Miller F. D Abu-raddad L. J 2010 Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt.Proc Natl Acad Sci USA 107 14757 14762 - 167.
Verbeeck J Peigue-lafeuille H Ross R. S et al 2008 HCV genotype 5: epidemiology and spread of an uncommon genotype.J Clin Virol 41 170 171 - 168.
Wong D. A Tong L. K Lim W 1998 High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong.Eur J Epidemiol 14 421 426 - 169.
Carenzi S & Rizzetto M. (Saracco G Olivero A Ciancio A 2003 Therapy of chronic hepatitis C: a critical review.Current Drug Targets in Infectious Disorders 3 25 32 - 170.
McHutchison JG & Fried MW 2003 Current therapy for hepatitis C: pegylated interferon and ribavirin.Clin Liver Dis 7 149 161 - 171.
Fried M. W Shiffman M. L Reddy K. R et al 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med 347 975 982 - 172.
Sette H Jr, Morgan TR et al. (Hadziyannis S. J 2004 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose.Ann Intern Med 140 346 355 - 173.
Di Bisceglie AM, Lindsay KL, et al. (Shiffman M. L 2004 Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.Gastroenterology 126 1015 1023 - 174.
Kamal S. M Nasser I. A 2008 Hepatitis C genotype 4: What we know and what we don’tyet know.Hepatology 47 1371 1383 - 175.
Nguyen M. H Keeffe E. B 2005 Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6.Clin Gastroenterol Hepatol 3, S97 S101 - 176.
Nguyen M. H Trinh H. N Garcia R Nguyen G Lam K. D Keeffe E. B 2008 Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.Am J Gastroenterol 103 1131 1135 - 177.
Rizzetto M andM Canese S Arico 1977 Immunofluorescence detection of a new antigen antibody system (Delta/anti-Delta) associated to hepatitis B virus in liver and serum of HBs Ag carriers.Gut 18 997 1003 - 178.
Sureau C Guerra B Lanford R. E 1993 Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion.J Virol 67 366 372 - 179.
Rizzetto M Ponzetto A Forzani I 1991 Epidemiology of hepatitis delta virus: overview.Prog Clin Biol Res 364 1 20 - 180.
Taylor J. M 2006 Hepatitis delta virus.Virology 344 71 76 - 181.
Radjef N Gordien E Ivaniushina V et al 2004 Molecular Phylogenetic Analyses Indicate a Wide and Ancient Radiation of African Hepatitis Delta Virus, Suggesting a Delta virus Genus of at Least Seven Major Clades.J Virol 78 2537 2544 - 182.
Gaeta G. B Stroffolini T Chiaramonte M et al 2000 Chronic hepatitis D: a vanishing disease? An Italian multicenter study.Hepatology 32 824 827 - 183.
Polish L. B Gallagher M Fields H. A Hadler S. C 1993 Delta hepatitis: molecular biology and clinical and epidemiological features.Clin Microbiol Rev 6 211 229 - 184.
Alcala de Monzon M, Rivero D, Perez M, Bracho A, Fields H. (Hadler S. C 1992 Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela.Am J Epidemiol 136 1507 1516 - 185.
Casey J. L 1996 Hepatitis delta virus. Genetics and pathogenesis.Clin Lab Med 16 451 464 - 186.
Rizzetto M 1983 The delta agent.Hepatology 3 729 737 - 187.
Casey J. L Brown T. L Colan E. J Wignall F. S Gerin J. L 1993 A genotype of hepatitis D virus that occurs in northern South America.Proc Natl Acad Sci USA 90 9016 9020 - 188.
Wu J. C Choo K. B Chen C. M Chen T. Z Huo T. I Lee S. D 1995 Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D.Lancet 346 939 941 - 189.
Bonino F Hoyer B Ford E Shih J. W Purcell R. H Gerin J. L 1981 The delta agent: HBsAg particles with delta antigen and RNA in the serum of an HBV carrier.Hepatology 1 127 131 - 190.
Wang K. S Choo Q. L Weiner A. J et al 1986 Structure, sequence and expression of the hepatitis delta (δ) viral genome.Nature 323, 508-514 (Erratum, 328,456, 1987) - 191.
Chao M Hsieh S. Y Taylor J 1990 Role of two forms of hepatitis delta virusantigen: evidence for a mechanism of self-limiting genome replication.J Virol 64 5066 5069 - 192.
Weiner A. Q Choo L Wang K. S et al 1988 A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides24and p27.J Virol 62, 594-599 - 193.
Luo G. X Chao M Hsieh S. Y et al 1990 A specific base transition occurs on replicating hepatitis delta virus RNA.J Virol 64 1021 1027 - 194.
Yamaguchi Y Filipovska J Yano K et al 2001 Stimulation of RNA polymerase II elongation by hepatitis delta antigen.Science 293 124 127 - 195.
Le Gal F Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, Dény2006 Eighth major clade for hepatitis delta virus.Emerg Infect Dis 12, 1447-1450 - 196.
Wu J. C Chen C. M Sheen I. J Lee S. D Tzeng H. M Choo K. B 1995 Evidence of transmission of hepatitis D virus to spouses from sequence analysis of the viral genome.Hepatology 22 1656 1660 - 197.
Di Bisceglie AM, Gerin JL, Casey JL. (Shakil A. O Hadziyannis S Hoofnagle J. H 1997 Geographic distribution and genetic variability of hepatitis delta virus genotype I.Virology 234 160 167 - 198.
Zhang Y. Y Tsega E Hansson B. G 1996 Phylogenetic analysis of hepatitis D viruses indicating a new genotype I subgroup among African isolates.J Clin Microbiol 34 3023 3030 - 199.
Niro G. A Smedile A Andriulli A Rizzetto M Gerin J. L Casey J. L 1997 The predominance of hepatitis delta virus genotype I among chronically infected Italian patients.Hepatology 25 728 734 - 200.
Wu J. C Chiang T. Y Sheen I. J 1998 Characterization and phylogenetic analysis of a novel hepatitis D virus strain discovered by restriction fragment length polymorphism analysis.J Gen Virol 79 1105 1113 - 201.
Watanabe H Nagayama K Enomoto N Chinzei R Yamashiro T Izumi N et al 2003 Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease.J Gen Virol 84 3275 3289 - 202.
Rizzetto M Hadziyannis S Hansson B. G Toukan A Gust I 1992 Hepatitis delta virus infection in the world: epidemiological patterns and clinical.Gastroenterol Internat 5 18 32 - 203.
Farci P 2001 Treatment of chronic hepatitis D.Infections in Medicine .18 10 - 204.
Hsu S. C Syu W. J Sheen I. J Liu H. T Jeng K. S Wu J. C 2002 Varied assembly and RNA editing efficiencies between genotypes I and II hepatitis D virus and their implications.Hepatology 35 665 672 - 205.
Ma S. P Sakugawa H Makino Y Tadano M Kinjo F Saito A 2003 The complete genomic sequence of hepatitis delta virus genotype IIb prevalent in Okinawa, Japan.J Gen Virol 84 461 464 - 206.
Niro G. A Rosina F Rizzetto M 2005 Treatment of hepatitis D.J Viral Hepat 12 2 9 - 207.
andPanda S. K Jameel S 1997 Hepatitis E virus: from epidemiology to molecular biology;Vir Hep Rev 3 227 251 - 208.
Jameel S 1999 Molecular biology and pathogenesis of hepatitis E virus;Expert Rev Mol Med 1 16 - 209.
andEmerson S. U Purcell R. H 2003 Hepatitis E Virus.Rev Med Virol 13 145 154 - 210.
Balayan M. S Andjaparidze A. G Savinskaya S. S et al 1983 Evidence for a virus in non-A non-B hepatitis transmitted via fecal-oral route.Intervirology 20 23 31 - 211.
Smith J. L 2001 A review of hepatitis E virus.J Food Prot 64 572 586 - 212.
Suzuki K andAikawa T Okamoto H 2002 Fulminant hepatitis E in Japan.N Engl J Med 347:1456 - 213.
Okamoto H Takahashi M Nishizawa T 2003 Features of hepatitis E virus infection in Japan.Intern Med 42 1065 1071 - 214.
Dalton H. R Bendall R Ijaz S Banks M 2008 Hepatitis E: an emerging infection in developed countries.Lancet Infect Dis 8 698 709 - 215.
Hamid S S Atiq M Shehzad F Yasmeen A Nissa T Salam A andSiddiqui A Jafri W 2002 Hepatitis E virus superinfection in patients with chronic liver disease;Hepatology 36 474 478 - 216.
Sheikh A Sugitani M Kinukawa N et al 2002 Hepatitis e virus infection in fulminant hepatitis patients and an apparently healthy population in Bangladesh.Am J Trop Med Hyg 66 721 724 - 217.
Khuroo M S Teli M R Skidmore S andSofi M. A Khuroo M I 1981 Incidence and severity of viral hepatitis in pregnancy.Am J Med 70 252 255 - 218.
Beniwal M Kumar A Kar P et al 2003 Prevalence and severity of acute viral hepatitis and fulminant hepatitis during pregnancy: a prospective study from North India.Indian J Med Microbiol 21 184 185 - 219.
Kumar A Beniwal B Kar P et al 2004 Hepatitis E in pregnancy. Int J Gynaecol Obstet85 240 244 - 220.
Krawczynski K andAggarwal R Kamili S 2000 Hepatitis E;Infect Dis Clin North Am 14 669 687 - 221.
ICTV Virus Taxonomy: Retrieved 2011-12-022009 release" - 222.
Reyes G. R Purdy M. A Kim J. P Luk K. C Young L. M Fry K. E Bradley D. W 1990 Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 247 1335 1339 - 223.
Reyes G. R Huang C. C Tam A. W Purdy M. A 1993 Molecular organization and replication of hepatitis E virus (HEV).Arch Virol 7 15 25 - 224.
Tam A. W Smith M. M Guerra M. E Huang C. C Bradley D. W andFry K. E Reyes G. R 1991 Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome;Virology 185 120 131 - 225.
Tam A. W White R Reed E Short M Zhang Y andFuerst T. R Lanford R. E 1996 In vitro propagation and production of hepatitis E virus from in vivo-infected primary macaque hepatocytes;Virology 215 1 9 - 226.
Ansari I H Nanda S K Durgapal H Agrawal S Mohanty S K Gupta D andJameel S Panda S. K 2000 Cloning, sequencing, and expression of the hepatitis E virus (HEV) nonstructural open reading frame 1 (ORF1);J Med Virol 60 275 283 - 227.
Zafrullah M Ozdener M H Kumar R andPanda S K Jameel S 1999 Mutational analysis of glycosylation, membrane translocation, and cell surface expression of the hepatitis E virus ORF2 protein;J Virol 73 4074 4082 - 228.
Graff J Torian U andNguyen H Emerson S. U 2006 A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus;J Virol 80 5919 5926 - 229.
Schlauder G. G Mushahwar I. K 2001 Genetic heterogeneity of hepatitis E virus.J Med Virol 65 282 292 - 230.
Okamoto H 2007 Genetic variability and evolution of hepatitis E virus.Virus Res 127 216 228 - 231.
andPurcell R. H Emerson S. U 2008 Hepatitis E: an emerging awareness of an old disease.J Hepatol 48 494 503 - 232.
Lam W. Y Chan R. C Sung J. J Chan P. K 2009 Genotype distribution and sequence variation of hepatitis E virus, Hong Kong.Emerg Infect Dis 15 792 794 - 233.
Arankalle V. A Chobe L. P Joshi M. V Chadha M. S Kundu B Walimbe A. M 2002 Human and swine hepatitis E virus from Western India belong to different genotypes.J Hepatol 36 417 425 - 234.
Cooper K Huang F. F Batista L et al 2003 Identification of genotype 3 hepatitis E virus (HEV) in serum and fecal samples from pigs in Thailand and Mexico, where genotype 1 and 2 HEV strains are prevalent in the respective human populations. J Clin Microbiol 43 1684 1688 - 235.
Meng X. J Halbur P. G Shapiro M. S et al 1998 Genetic and experimental evidence for cross-species infection by swine hepatitis E virus.J Virol 72 9714 9721 - 236.
Ohnishi S Kang J. H Maekubo H et al 2006 Comparison of clinical features of acute hepatitis caused by hepatitis E virus (HEV) genotypes 3 and 4 in Sapporo, Japan.Hepatol Res 36 301 307 - 237.
Chobe L. P Lole K. S Arankalle V. A 2006 Full genome sequence and analysis of Indian swine hepatitis E virus isolate of genotype 4.Vet Microbiol 114 240 251 - 238.
Viswanathan R 1957 Infectious hepatitis in Dehli (1955-56): a critical study; epidemiology. Indian J Med Res45 1 30 - 239.
Kar P Jilani N Husain S. A Pasha S. T Anand R Rai A Das B. C 2008 Does hepatitis E viral load and genotypes influence the final outcome of acute liver failure during pregnancy?Am J Gastroenterol 103 2495 2501 - 240.
Mizuo H Yazaki Y Sugawara K Tsuda F Takahashi M Nishizawa T Okamoto H 2005 Possible risk factors for the transmission of hepatitis E virus and for the severe form of hepatitis E acquired locally in Hokkaido, Japan.J Med Virol 76 341 349 - 241.
Abe T Aikawa T Akahane Y Arai M Asahina Y Atarashi Y et al 2006 Demographic, epidemiological, and virological characteristics of hepatitis E virus infections in Japan based on 254 human cases collected nationwide [in Japanese]. Kanzo.47 384 91 - 242.
Péron J. M Bureau C Poirson H et al 2007 Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy.J Viral Hepat 14 298 303 - 243.
Inoue J Takahashi M Mizuo H Suzuki K Aikawa T Shimosegawa T Okamoto H 2009 Nucleotide substitutions of hepatitis E virus genomes associated with fulminant hepatitis and disease severity.Tohoku J Exp Med 218 279 284 - 244.
Mammen MP Jr, Thapa GB, ThapaN, et al. (Shrestha M. P Scott R. M Joshi D. M 2007 Safety and efficacy of a recombinant hepatitis E vaccine.N Engl J Med 356 895 903